Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Arvinas stock

Learn how to easily invest in Arvinas stock.

Arvinas Inc is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Arvinas employs 280 staff and has a trailing 12-month revenue of around $91.1 million.

How to buy shares in Arvinas

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Arvinas stock price (NASDAQ: ARVN)

Use our graph to track the performance of ARVN stocks over time.

Arvinas shares at a glance

Information last updated 2022-09-26.
Latest market close$42.06
52-week range$34.90 - $97.33
50-day moving average $48.93
200-day moving average $57.47
Wall St. target price$91.30
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.18

Buy Arvinas shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Arvinas stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arvinas price performance over time

Historical closes compared with the close of $42.06 from 2022-09-23

1 week (2022-09-19) -9.84%
1 month (2022-08-26) -4.88%
3 months (2022-06-24) -8.17%
6 months (2022-03-22) N/A
1 year (2021-09-24) -52.53%
2 years (2020-09-25) 72.24%
3 years (2019-09-26) 78.67%
5 years (2017-09-22) N/A

Arvinas financials

Revenue TTM $91.1 million
Gross profit TTM $46.7 million
Return on assets TTM -14.02%
Return on equity TTM -37.19%
Profit margin -255.87%
Book value $12.61
Market capitalisation $2.2 billion

TTM: trailing 12 months

Arvinas share dividends

We're not expecting Arvinas to pay a dividend over the next 12 months.

Arvinas share price volatility

Over the last 12 months, Arvinas's shares have ranged in value from as little as $34.9 up to $97.33. A popular way to gauge a stock's volatility is its "beta".

ARVN.US volatility(beta: 2.06)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 2.0601. This would suggest that Arvinas's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Arvinas overview

Arvinas, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc. , Genentech, Inc. , F. Hoffman-La Roche Ltd.

Frequently asked questions

What percentage of Arvinas is owned by insiders or institutions?
Currently 11.51% of Arvinas shares are held by insiders and 97.024% by institutions.
How many people work for Arvinas?
Latest data suggests 280 work at Arvinas.
When does the fiscal year end for Arvinas?
Arvinas's fiscal year ends in December.
Where is Arvinas based?
Arvinas's address is: 5 Science Park, New Haven, CT, United States, 06511
What is Arvinas's ISIN number?
Arvinas's international securities identification number is: US04335A1051
What is Arvinas's CUSIP number?
Arvinas's Committee on Uniform Securities Identification Procedures number is: 04335A105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site